<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109616">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01677286</url>
  </required_header>
  <id_info>
    <org_study_id>H-31546</org_study_id>
    <nct_id>NCT01677286</nct_id>
  </id_info>
  <brief_title>Safety and Effect of Doxycycline in Patients With Amyloidosis</brief_title>
  <official_title>A Phase II Study of Doxycycline in Patients With Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The tetracycline antibiotic doxycycline disrupts A beta amyloid fibrils (AB) in Alzheimer's
      disease, transthyretin (ATTR) amyloid fibrils in familial amyloidotic polyneuropathy, and
      immunoglobulin light chain (AL) amyloid fibrils in transgenic mouse models of disease. If
      untreated, amyloid deposits impair organ function, affecting the morbidity and mortality of
      patients.

      This single-center, twelve-month, open-label, prospective, pilot phase II study aims to
      determine whether doxycycline reduces amyloid deposits and improves organ function in
      patients with systemic or localized amyloidosis.

      The investigators plan to enroll patients with measurable amyloid disease according to
      internationally-accepted diagnostic criteria. Patients must have stable organ function at
      enrollment. Eligible subjects not receiving active treatments for amyloidosis affecting
      their kidneys, heart, aerodigestive tracts, peripheral or autonomic nervous system(s),
      lungs, eyes, skin, bladder, or breasts will undergo evaluations at baseline, 6 months, and
      12 months - or more frequently as clinically indicated.

      Over 45 years experience indicates doxycycline is a safe, well tolerated antibiotic. The
      investigators will use standard grading systems to assess doxycycline response following
      twelve months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite measures specific to the organ system affected by amyloidosis at study entry</measure>
    <time_frame>12 months</time_frame>
    <description>Amyloid nephropathy: 24 hour urine protein excretion, creatinine clearance
Amyloid cardiomyopathy: cardiac biomarkers (BNP, Troponin I), echo parameters (IVSd, longitudinal strain, diastolic indices [e/e']), ECG
Amyloid peripheral neuropathy: Neurologic Impairment Score-Lower Limb (NIS-LL), modified body mass index (mBMI)
Amyloid autonomic neuropathy: postural blood pressures, heart rate variability, mBMI
Localized amyloidosis:
airway -- PFTs, CT imaging, endoscopic visualization
gastrointestinal -- endoscopic visualization
bladder -- CT imaging, cystoscopy, urodynamics
skin -- direct measures of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of Life (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kumamoto neurologic score</measure>
    <time_frame>12 months</time_frame>
    <description>Motor, sensory, autonomic measures of neuropathy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>doxycycline 100 mg po bid x 12 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 100 mg po bid x 12 months</intervention_name>
    <description>100mg by mouth twice daily for 1 year.</description>
    <arm_group_label>doxycycline 100 mg po bid x 12 months</arm_group_label>
    <other_name>CAS: 564-25-0; ATC code: J01AA02 A01AB22; PubChem: CID 11256</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Biopsy-proven amyloidosis

          -  Biochemical or clinical evidence of amyloid induced end-organ dysfunction

        Exclusion Criteria:

          -  Concurrent use of other tetracyclines

          -  Ongoing active treatment for amyloidosis

          -  Pregnancy or unwillingness to use contraception by women of childbearing age

          -  Doxycycline drug allergy/hypersensitivity

          -  ECOG performance status &gt; 3

          -  NYHA class &gt; 3

          -  Renal insufficiency (estimated creatinine clearance &lt; 25 ml/min)

          -  Transaminitis (AST or ALT &gt; 5 times upper limit of normal)

          -  Diabetes mellitus or hemoglobin A1C &gt; 6.2%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John L Berk, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cardoso I, Merlini G, Saraiva MJ. 4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003 May;17(8):803-9.</citation>
    <PMID>12724338</PMID>
  </reference>
  <reference>
    <citation>Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006 Feb;20(2):234-9.</citation>
    <PMID>16449795</PMID>
  </reference>
  <reference>
    <citation>Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001 Jan 5;487(3):404-7.</citation>
    <PMID>11163366</PMID>
  </reference>
  <reference>
    <citation>Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C, Jasuja R, Trinkaus-Randall V, Liao R, Connors LH, Seldin DC. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011 Dec 15;118(25):6610-7. doi: 10.1182/blood-2011-04-351643.</citation>
    <PMID>21998211</PMID>
  </reference>
  <reference>
    <citation>Obici L, Cortese A, Lozza A, Lucchetti J, Gobbi M, Palladini G, Perlini S, Saraiva MJ, Merlini G. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012 Jun;19 Suppl 1:34-6. doi: 10.3109/13506129.2012.678508.</citation>
    <PMID>22551192</PMID>
  </reference>
  <reference>
    <citation>Giorgetti S, Raimondi S, Pagano K, Relini A, Bucciantini M, Corazza A, Fogolari F, Codutti L, Salmona M, Mangione P, Colombo L, De Luigi A, Porcari R, Gliozzi A, Stefani M, Esposito G, Bellotti V, Stoppini M. Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem. 2011 Jan 21;286(3):2121-31. doi: 10.1074/jbc.M110.178376. Epub 2010 Nov 10.</citation>
    <PMID>21068391</PMID>
  </reference>
  <reference>
    <citation>Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010 Jul 30;8:74. doi: 10.1186/1479-5876-8-74.</citation>
    <PMID>20673327</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 2, 2015</lastchanged_date>
  <firstreceived_date>August 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>John L. Berk</investigator_full_name>
    <investigator_title>Clinical Director, Amyloid Treatment &amp; Research Program</investigator_title>
  </responsible_party>
  <keyword>AL Amyloidosis</keyword>
  <keyword>Primary Amyloidosis</keyword>
  <keyword>Hereditary Amyloidosis</keyword>
  <keyword>Familial Amyloidosis</keyword>
  <keyword>SSA Amyloidosis</keyword>
  <keyword>Senile Systemic Amyloidosis</keyword>
  <keyword>AA Amyloidosis</keyword>
  <keyword>Secondary Amyloidosis</keyword>
  <keyword>Localized Amyloidosis</keyword>
  <keyword>Systemic Amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
